Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 17,8x - 19,7x | 18,8x |
| Selected Fwd EBITDA Multiple | 17,0x - 18,7x | 17,9x |
| Fair Value | ₹53,84 - ₹59,51 | ₹56,68 |
| Upside | 14,2% - 26,2% | 20,2% |
| Benchmarks | Ticker | Full Ticker |
| Hikal Limited | 524735 | BSE:524735 |
| Lupin Limited | 500257 | BSE:500257 |
| Supriya Lifescience Limited | 543434 | BSE:543434 |
| Emcure Pharmaceuticals Limited | 544210 | BSE:544210 |
| Dr. Reddy's Laboratories Limited | 500124 | BSE:500124 |
| Morepen Laboratories Limited | MOREPENLAB | NSEI:MOREPENLAB |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| 524735 | 500257 | 543434 | 544210 | 500124 | MOREPENLAB | ||
| BSE:524735 | BSE:500257 | BSE:543434 | BSE:544210 | BSE:500124 | NSEI:MOREPENLAB | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 4.2% | 16.6% | 19.6% | 16.2% | 16.3% | 21.1% | |
| 3Y CAGR | -0.6% | 37.0% | 6.9% | 3.0% | 23.0% | 9.7% | |
| Latest Twelve Months | 9.0% | 32.5% | 48.9% | 22.1% | 12.0% | -8.3% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 16.1% | 15.5% | 35.0% | 19.1% | 25.5% | 8.8% | |
| Prior Fiscal Year | 14.9% | 18.1% | 30.7% | 17.7% | 28.4% | 9.1% | |
| Latest Fiscal Year | 17.9% | 22.2% | 37.4% | 17.9% | 27.3% | 10.5% | |
| Latest Twelve Months | 16.2% | 23.1% | 37.4% | 18.0% | 26.7% | 9.2% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.36x | 3.85x | 7.40x | 3.34x | 2.94x | 1.44x | |
| EV / LTM EBITDA | 14.5x | 16.7x | 19.8x | 18.5x | 11.0x | 15.7x | |
| EV / LTM EBIT | 27.2x | 20.0x | 21.5x | 24.2x | 13.5x | 19.4x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | 11.0x | 16.7x | 19.8x | ||||
| Historical EV / LTM EBITDA | 11.7x | 13.4x | 20.0x | ||||
| Selected EV / LTM EBITDA | 17.8x | 18.8x | 19.7x | ||||
| (x) LTM EBITDA | 1,654 | 1,654 | 1,654 | ||||
| (=) Implied Enterprise Value | 29,503 | 31,055 | 32,608 | ||||
| (-) Non-shareholder Claims * | 0 | 0 | 0 | ||||
| (=) Equity Value | 29,503 | 31,055 | 32,608 | ||||
| (/) Shares Outstanding | 548.0 | 548.0 | 548.0 | ||||
| Implied Value Range | 53.84 | 56.68 | 59.51 | ||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 53.84 | 56.68 | 59.51 | 47.14 | |||
| Upside / (Downside) | 14.2% | 20.2% | 26.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 524735 | 500257 | 543434 | 544210 | 500124 | MOREPENLAB | |
| Enterprise Value | 35,763 | 900,049 | 51,423 | 262,431 | 982,775 | 25,831 | |
| (+) Cash & Short Term Investments | 0 | 29,899 | 792 | 0 | 66,688 | 0 | |
| (+) Investments & Other | 0 | 0 | 632 | 0 | 11,419 | 0 | |
| (-) Debt | 0 | (54,478) | (54) | 0 | (48,644) | 0 | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | (3,696) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 35,763 | 875,470 | 52,793 | 262,431 | 1,008,542 | 25,831 | |
| (/) Shares Outstanding | 123.3 | 456.7 | 80.5 | 189.5 | 832.4 | 548.0 | |
| Implied Stock Price | 290.05 | 1,916.75 | 655.95 | 1,384.80 | 1,211.65 | 47.14 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 290.05 | 1,916.75 | 655.95 | 1,384.80 | 1,211.65 | 47.14 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |